Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – SomaLogic Completes Agreement With Bristol-Myers Squibb for Expanded Access to SOMAmer(R) Reagents

[Marketwired] – SomaLogic, Inc., announced today that it has signed an agreement with the Bristol-Myers Squibb Company to provide expanded access to its proprietary SOMAmer reagents. The agreement covers both the 1,310 … Read more on this. Bristol-Myers Squibb Company (BMY) , with a current value of $104.59B, began trading this morning at $63.71. During today’s session, BMY traded between $61.98 to $63.99 with a one year range of $51.82 to $70.87. Bristol-Myers Squibb (BMY) shares are currently priced at 33.31x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -3.59x earnings multiple for the same period. And for those looking to make a return holding the stock, the company pays shareholders $1.52 per share annually in dividends, yielding 2.21%. Consensus earnings for the current quarter by the 18 sell-side analysts covering the stock is an estimate of $0.28 per share, which would be $0.18 worse than the year-ago quarter and a $0.03 sequential increase. The full-year EPS estimate is $1.91, which would be a $0.06 better than last year. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $4.12 Billion. If realized, that would be a 3.29% decrease over the year-ago quarter. More recently, Piper Jaffray upgraded BMY from Underweight to Neutral (Aug 24, 2015). Previously, Piper Jaffray Initiated BMY at to Underweight. The average price target for BMY shares by the analysts covering it is $74.05, which is 16.23% above where the stock opened. See more in (NYSE:BMY) Similar Articles: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb’s Opdivo (nivolumab) Recipient of Prix Galien USA 2015 Award for Best Biotechnology Product Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Selects ZS to Support Global Commercial Analytics Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Establishes Collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) Program in the U.S.